Cargando…

Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2

Gout is a common inflammatory disease. The activation of NLRP3 inflammasome induced by monosodium urate (MSU) crystals has a critical role in gout, and its prevention is beneficial for patients. Lipoxin A4 (LXA4) is an endogenous lipoxygenase-derived eicosanoid mediator with powerful anti-inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, You, Chen, Yongjun, Zhong, Xiaowu, Xia, Hongtao, Zhao, Mingcai, Zhao, Mengyuan, Xu, Lei, Guo, Xiaolan, You, Chong-Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772058/
https://www.ncbi.nlm.nih.gov/pubmed/36569930
http://dx.doi.org/10.3389/fimmu.2022.1060441
_version_ 1784854923799691264
author Zhou, You
Chen, Yongjun
Zhong, Xiaowu
Xia, Hongtao
Zhao, Mingcai
Zhao, Mengyuan
Xu, Lei
Guo, Xiaolan
You, Chong-Ge
author_facet Zhou, You
Chen, Yongjun
Zhong, Xiaowu
Xia, Hongtao
Zhao, Mingcai
Zhao, Mengyuan
Xu, Lei
Guo, Xiaolan
You, Chong-Ge
author_sort Zhou, You
collection PubMed
description Gout is a common inflammatory disease. The activation of NLRP3 inflammasome induced by monosodium urate (MSU) crystals has a critical role in gout, and its prevention is beneficial for patients. Lipoxin A4 (LXA4) is an endogenous lipoxygenase-derived eicosanoid mediator with powerful anti-inflammatory properties. However, whether LXA4 can suppress NLRP3 inflammasome activation induced by MSU crystals remains unclear. This study aimed to investigate the protective effect of LXA4 on MSU-crystal-induced NLRP3 inflammasome activation and its underlying molecular mechanisms. We found that LXA4 inhibited MSU-crystal-induced NLRP3 inflammasome activation, interleukin (IL)-1β maturation, and pyroptosis. More specifically, LXA4 suppressed the assembly of the NLRP3 inflammasome, including oligomerization and speck formation of ASC, and ASC-NLRP3 interaction. Furthermore, LXA4 suppressed oxidative stress, the upstream events for NLRP3 inflammasome activation, as evidenced by the fact that LXA4 eliminated total reactive oxygen species (ROS) generation and alleviated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and mitochondrial dysfunction. However, LXA4 also depressed the Nrf2 activation, a critical molecule in the antioxidant pathway, and then exerted an inhibitory impact on Klf9 expression and promotional impact on TXNRD2 expression, two molecules located downstream of Nrf2 in sequence. Knockdown of TXNRD2 reversed the LXA4-induced depression of ROS and NLRP3 inflammasome. Moreover, LXA4 alleviated joint inflammation and decreased the production of cleaved caspase-1 and matured IL-1β in gouty arthritis rats. Taken together, our findings demonstrate that LXA4 can attenuate MSU-crystal-induced NLRP3 inflammasome activation, probably through suppressing Nrf2 activation to increase TXNRD2 expression. The present study highlights the potential of LXA4 as an attractive new gout treatment candidate.
format Online
Article
Text
id pubmed-9772058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97720582022-12-23 Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2 Zhou, You Chen, Yongjun Zhong, Xiaowu Xia, Hongtao Zhao, Mingcai Zhao, Mengyuan Xu, Lei Guo, Xiaolan You, Chong-Ge Front Immunol Immunology Gout is a common inflammatory disease. The activation of NLRP3 inflammasome induced by monosodium urate (MSU) crystals has a critical role in gout, and its prevention is beneficial for patients. Lipoxin A4 (LXA4) is an endogenous lipoxygenase-derived eicosanoid mediator with powerful anti-inflammatory properties. However, whether LXA4 can suppress NLRP3 inflammasome activation induced by MSU crystals remains unclear. This study aimed to investigate the protective effect of LXA4 on MSU-crystal-induced NLRP3 inflammasome activation and its underlying molecular mechanisms. We found that LXA4 inhibited MSU-crystal-induced NLRP3 inflammasome activation, interleukin (IL)-1β maturation, and pyroptosis. More specifically, LXA4 suppressed the assembly of the NLRP3 inflammasome, including oligomerization and speck formation of ASC, and ASC-NLRP3 interaction. Furthermore, LXA4 suppressed oxidative stress, the upstream events for NLRP3 inflammasome activation, as evidenced by the fact that LXA4 eliminated total reactive oxygen species (ROS) generation and alleviated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and mitochondrial dysfunction. However, LXA4 also depressed the Nrf2 activation, a critical molecule in the antioxidant pathway, and then exerted an inhibitory impact on Klf9 expression and promotional impact on TXNRD2 expression, two molecules located downstream of Nrf2 in sequence. Knockdown of TXNRD2 reversed the LXA4-induced depression of ROS and NLRP3 inflammasome. Moreover, LXA4 alleviated joint inflammation and decreased the production of cleaved caspase-1 and matured IL-1β in gouty arthritis rats. Taken together, our findings demonstrate that LXA4 can attenuate MSU-crystal-induced NLRP3 inflammasome activation, probably through suppressing Nrf2 activation to increase TXNRD2 expression. The present study highlights the potential of LXA4 as an attractive new gout treatment candidate. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9772058/ /pubmed/36569930 http://dx.doi.org/10.3389/fimmu.2022.1060441 Text en Copyright © 2022 Zhou, Chen, Zhong, Xia, Zhao, Zhao, Xu, Guo and You https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, You
Chen, Yongjun
Zhong, Xiaowu
Xia, Hongtao
Zhao, Mingcai
Zhao, Mengyuan
Xu, Lei
Guo, Xiaolan
You, Chong-Ge
Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title_full Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title_fullStr Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title_full_unstemmed Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title_short Lipoxin A4 attenuates MSU-crystal-induced NLRP3 inflammasome activation through suppressing Nrf2 thereby increasing TXNRD2
title_sort lipoxin a4 attenuates msu-crystal-induced nlrp3 inflammasome activation through suppressing nrf2 thereby increasing txnrd2
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772058/
https://www.ncbi.nlm.nih.gov/pubmed/36569930
http://dx.doi.org/10.3389/fimmu.2022.1060441
work_keys_str_mv AT zhouyou lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT chenyongjun lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT zhongxiaowu lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT xiahongtao lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT zhaomingcai lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT zhaomengyuan lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT xulei lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT guoxiaolan lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2
AT youchongge lipoxina4attenuatesmsucrystalinducednlrp3inflammasomeactivationthroughsuppressingnrf2therebyincreasingtxnrd2